SomaLogic, Inc.

SomaLogic, Inc. (Nasdaq: SLGC) is a life sciences and proteomics company that entered public markets in 2021 through a business combination with CM Life Sciences III Inc., a special purpose acquisition company sponsored by CM Life Sciences, an entity affiliated with Casdin Capital and Foresite Capital. The company develops the SomaScan platform, a proprietary protein biomarker measurement technology used across drug development, clinical research, and diagnostics. SomaLogic filed an 8-K with the Securities and Exchange Commission on October 4, 2023, during an active period of corporate activity for the Boulder, Colorado-based company. SLGC operates within the life sciences tools and diagnostics sector. Sign up at SpacDesk for full data, filings, and analytics on SLGC and hundreds of other SPAC-linked companies.